product summary
Loading...
company name :
R&D Systems
product type :
protein
product name :
Recombinant Mouse PD-L1/B7-H1 Fc Chimera Protein, CF
catalog :
1019-B7-100
quantity :
100 ug
price :
400 USD
more info or order :
R&D Systems product webpage
citations: 22
Reference
Corria Osorio J, Carmona S, Stefanidis E, Andreatta M, Ortiz Miranda Y, Muller T, et al. Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells. Nat Immunol. 2023;24:869-883 pubmed publisher
Meerschaert K, Edwards B, Epouhe A, Jefferson B, Friedman R, Babyok O, et al. Neuronally expressed PDL1, not PD1, suppresses acute nociception. Brain Behav Immun. 2022;106:233-246 pubmed publisher
Martins C, Silva M, Rasbach E, Singh P, Itoh Y, Williams J, et al. Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells. Sci Rep. 2022;12:12491 pubmed publisher
Bryan C, Rocklin G, Bick M, Ford A, Majri Morrison S, Kroll A, et al. Computational design of a synthetic PD-1 agonist. Proc Natl Acad Sci U S A. 2021;118: pubmed publisher
Thanabalasuriar A, Chiang A, Morehouse C, Camara M, Hawkins S, Keller A, et al. PD-L1+ neutrophils contribute to injury-induced infection susceptibility. Sci Adv. 2021;7: pubmed publisher
Hanson A, Elpek K, Duong E, Shallberg L, Fan M, Johnson C, et al. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS ONE. 2020;15:e0239595 pubmed publisher
Zalba S, Contreras Sandoval A, Martisova E, Debets R, Smerdou C, Garrido M. Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs. Pharmaceutics. 2020;12: pubmed publisher
Garrett Thomson S, Massimi A, Fedorov E, Bonanno J, Scandiuzzi L, Hillerich B, et al. Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex. PLoS ONE. 2020;15:e0233578 pubmed publisher
Garo L, Ajay A, Fujiwara M, Beynon V, Kuhn C, Gabriely G, et al. Smad7 Controls Immunoregulatory PDL2/1-PD1 Signaling in Intestinal Inflammation and Autoimmunity. Cell Rep. 2019;28:3353-3366.e5 pubmed publisher
Nakajima M, Sakoda Y, Adachi K, Nagano H, Tamada K. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells. Cancer Sci. 2019;110:3079-3088 pubmed publisher
von Knethen A, Schäfer A, Kuchler L, Knape T, Christen U, Hintermann E, et al. Tolerizing CTL by Sustained Hepatic PD-L1 Expression Provides a New Therapy Approach in Mouse Sepsis. Theranostics. 2019;9:2003-2016 pubmed publisher
Xue X, Wu J, Li J, Xu J, Dai H, Tao C, et al. Indirubin attenuates mouse psoriasis-like skin lesion in a CD274-dependent manner: an achievement of RNA sequencing. Biosci Rep. 2018;38: pubmed publisher
Tsukamoto H, Fujieda K, Miyashita A, Fukushima S, Ikeda T, Kubo Y, et al. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment. Cancer Res. 2018;78:5011-5022 pubmed publisher
Nakagawa S, Serada S, Kakubari R, Hiramatsu K, Sugase T, Matsuzaki S, et al. Intratumoral Delivery of an Adenoviral Vector Carrying the SOCS-1 Gene Enhances T-Cell-Mediated Antitumor Immunity By Suppressing PD-L1. Mol Cancer Ther. 2018;17:1941-1950 pubmed publisher
Rios Doria J, Harper J, Rothstein R, Wetzel L, Chesebrough J, MARRERO A, et al. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies. Cancer Res. 2017;77:2686-2698 pubmed publisher
Kinosada H, Yasunaga J, Shimura K, Miyazato P, Onishi C, Iyoda T, et al. HTLV-1 bZIP Factor Enhances T-Cell Proliferation by Impeding the Suppressive Signaling of Co-inhibitory Receptors. PLoS Pathog. 2017;13:e1006120 pubmed publisher
Kleinpeter P, Fend L, Thioudellet C, Geist M, Sfrontato N, Koerper V, et al. Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition. Oncoimmunology. 2016;5:e1220467 pubmed
Shirakawa K, Yan X, Shinmura K, Endo J, Kataoka M, Katsumata Y, et al. Obesity accelerates T cell senescence in murine visceral adipose tissue. J Clin Invest. 2016;126:4626-4639 pubmed publisher
McAlees J, Lajoie S, Dienger K, Sproles A, Richgels P, Yang Y, et al. Differential control of CD4(+) T-cell subsets by the PD-1/PD-L1 axis in a mouse model of allergic asthma. Eur J Immunol. 2015;45:1019-29 pubmed publisher
Xiao Y, Yu S, Zhu B, Bedoret D, Bu X, Francisco L, et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med. 2014;211:943-59 pubmed publisher
Drees J, Augustin L, Mertensotto M, Schottel J, Leonard A, Saltzman D. Soluble production of a biologically active single-chain antibody against murine PD-L1 in Escherichia coli. Protein Expr Purif. 2014;94:60-6 pubmed publisher
Butte M, Keir M, Phamduy T, Sharpe A, Freeman G. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27:111-22 pubmed
image
image 1 :
R&D Systems 1019-B7-100 image 1
Recombinant Mouse PD-L1/B7-H1 Fc Chimera Protein Bioactivity
product information
brand :
R&D Systems, a Bio-Techne Brand
catalog number base :
1019-B7
SKU :
1019-B7-100
product name :
Recombinant Mouse PD-L1/B7-H1 Fc Chimera Protein, CF
Description :
The Recombinant Mouse PD-L1/B7-H1 Fc Chimera Protein, CF from R&D Systems is derived from NS0. The Recombinant Mouse PD-L1/B7-H1 Fc Chimera Protein, CF has been validated for the following applications: Bioactivity.
target :
PD-L1/B7-H1
category :
Proteins and Enzymes
unit size :
100 ug
buffer :
Lyophilized from a 0.2 µm filtered solution in PBS.
conjugate :
Unconjugated
purity :
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
species :
Mouse
observed molecular weight :
75-85 kDa, reducing conditions
theoretical molecular weight :
51.3 kDa (monomer)
gene symbol :
Cd274
details of functionality :
Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated mouse T cells. The ED50 for this effect is 0.15-0.75 µg/mL.
endotoxin note :
<0.10 EU per 1 µg of the protein by the LAL method.
accessionNumbers :
Q9EP73
applications :
Bioactivity
source :
NS0-derived Recombinant Mouse PD-L1/B7-H1 Fc Chimera Protein
USD :
400 USD
alt names :
Avelumab, B7-H, B7H1, B7-H1, B7H1PDCD1L1, CD274, CD274 antigenMGC142294, CD274 molecule, PDCD1L1, PDCD1LG1, PDCD1LG1MGC142296, PDL1, PD-L1, PD-L1B7 homolog 1, PDL1PDCD1 ligand 1, programmed cell death 1 ligand 1, Programmed death ligand 1
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.
more info or order :
R&D Systems product webpage
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.